Bioventus completes Misonix acquisition; $183M cash plus 18.3M shares issued

Bioventus Inc.

Misonix shareholders received $28 cash or 1.6839 BVS shares per share; total consideration $182.99M cash and 18.34M BVS shares.
New $262M term loan added to finance the merger; $80M of existing Bioventus term loan prepaid.
Stavros Vizirgiankis and Patrick Beyer appointed to Bioventus board effective closing.
Combined company targets $15B addressable market; expects double-digit revenue growth.
Misonix becomes wholly owned subsidiary of Bioventus; operations continue.

item 1.01 item 2.01 item 2.03 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Patrick J. Beyer

Director

BVS · Bioventus Inc.

Effective: 2021-10-29
Filed: October 29, 2021, 7:59 PM ET

The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.

Appointed

Stavros G. Vizirgiankis

Director

BVS · Bioventus Inc.

Effective: 2021-10-29
Filed: October 29, 2021, 7:59 PM ET

The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick J. Beyer was appointed as Director at Bioventus Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stavros G. Vizirgiankis was appointed as Director at Bioventus Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.

View on SEC.gov

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-313521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.